# Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

> **NCT00334126** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 399 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated

## Key facts

- **NCT ID:** NCT00334126
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 399 (ACTUAL)
- **Last updated:** 2011-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334126, "Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00334126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*